Trastuzumab plus paclitaxel could increase the therapeutic effect in HER2+ BC (Pegram et al., 2000; Ding et al., 2017; Wang et al., 2017; Zhang et al., 2020). This evidence concerns the gene ERBB2 and breast cancer.